One possibility is that anti-TIGIT blockade provides complementary anti-tumor activities to the IFN-γ pathway by reinforcing the granzyme B and perforin activations (Figure 6 and Supplementary Figure 7). This evidence concerns the gene PRF1 and neoplasm.